Skip to main content
SpringerLink
Log in
Book cover

Vascular Embolotherapy pp 177–188Cite as

Embolotherapy for Neuroendocrine Tumor Hepatic Metastases

  • Chapter

  • 821 Accesses

Part of the book series: Medical Radiology ((Med Radiol Diagn Imaging))

14.7 Conclusion

Current management strategies for neuroendocrine tumor hepatic metastases have relied on data from anecdotal evidence and retrospective studies involving small numbers of patients. It is unlikely that this situation will change in the near future, since prospective studies are difficult to perform in such a relatively rare and biologically heterogeneous disease. Embolotherapy is a widely accepted method of treatment for nonresectable hepatic metastases from neuroendocrine tumors. Long-term palliation of pain and hormonal symptoms is possible using repeated treatment. Both bland hepatic artery embolization and chemoembolization have been used, and there is no conclusive data to indicate which embolization method and which embolic agents are most efficacious.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lepage C, Bouvier AM, Phelip JM, et al. (2004) Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut 53:549–553

    Article  PubMed  CAS  Google Scholar 

  2. Moertel CG (1987) An odyssey in the land of small tumors. J Clin Oncol 5:1503–1522

    Google Scholar 

  3. Soreide O, Berstad T, Bakka A (1992) Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 111:48

    PubMed  CAS  Google Scholar 

  4. Hemminki K, Li X (2001) Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 92:2204–10

    Article  PubMed  CAS  Google Scholar 

  5. Quaedvlieg PF, Visser O, Lamers CB, et al. (2001) Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol 12:1295–300

    Article  PubMed  CAS  Google Scholar 

  6. Hochwald SN, Zee S, Conlon KC, et al. (2002) Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20:2633–42

    Article  PubMed  Google Scholar 

  7. Shebani KO, Souba WW, Finkelstein DM, et al. (1999) Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 229:815–21

    Article  PubMed  CAS  Google Scholar 

  8. Madeira I, Terris B, Voss M, et al. (1998) Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 43:422–7

    PubMed  CAS  Google Scholar 

  9. Godwin JD II (1975) Carcinoid tumors: An analysis of 2837 cases. Cancer 36:560–569

    PubMed  Google Scholar 

  10. Zeitels J, Naunheim K, Kaplan EL, et al. (1982) Carcinoid tumors: A 37 year experience. Arch Surg 117:732–737

    PubMed  CAS  Google Scholar 

  11. Mignon M, Ruszniewski P, Haffar S, et al. (1986) Current approach to the management of tumoral process in patients with gastrinoma. World J Surg 10:703–710

    Article  PubMed  CAS  Google Scholar 

  12. Creutzfeldt W (1996) Carcinoid tumors: development of our knowledge. World J Surg 20:126–131

    Article  PubMed  CAS  Google Scholar 

  13. Arnold R, Frank M, Kajdan U (1994) Management of gastroenteropancreatic endocrine tumors: The place of somatostatin analogues. Digestion 55(Suppl 3):107–113

    PubMed  Google Scholar 

  14. Öberg K, Erikson B (1989) Medical treatment of neuroendocrine gut and pancreatic tumors. Acta Oncol 28:425–431

    PubMed  Google Scholar 

  15. Ruszniewski P, Ducreux M, Chayvialle JA, et al. (1996) Treatment of the carcinoid syndrome with the long acting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 39:279–283

    PubMed  CAS  Google Scholar 

  16. Arnold R (1996) Medical treatment of metastasizing carcinoid tumors. World J Surg 20:203–207

    Article  PubMed  CAS  Google Scholar 

  17. Eriksson B, Skogseid B, Lundqvist G, et al. (1990) Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 65:1883–1890

    PubMed  CAS  Google Scholar 

  18. Chiti A, Fanti S, Savelli G, et al. (1998) Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastroentero-pancreatic tumours. Eur J Nucl Med 25:1396–1403

    Article  PubMed  CAS  Google Scholar 

  19. Gibril F, Reynolds JC, Doppman JL, et al. (1996) Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 125:26–34

    PubMed  CAS  Google Scholar 

  20. Frucht H, Doppman JL, Norton JA, et al. (1989) Gastrinomas: comparison of MR imaging with CT, angiography, and US. Radiology 171:713–717

    PubMed  CAS  Google Scholar 

  21. Zimmer T, Ziegler K, Bader M, et al. (1994) Localization of neuroendocrine tumours of the upper gastrointestinal tract. Gut 35:471–475

    PubMed  CAS  Google Scholar 

  22. Zimmer T, Stolzel U, Bader M, et al. (1996) Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localization of insulinomas and gastrinomas. Gut 39:562–568

    PubMed  CAS  Google Scholar 

  23. Anthuber M, Jauch KW, Briegel J, et al. (1996) Results of liver transplantation for gastroenteropancreatic tumor metastases. World J Surg 20:73–76

    Article  PubMed  CAS  Google Scholar 

  24. Ahlman H, Westberg G, Wangberg B, et al. (1996) Treatment of liver metastases of carcinoid tumors. World J Surg 20:196–202

    Article  PubMed  CAS  Google Scholar 

  25. Chamberlain RS, Canes D, Brown KT, et al. (2000) Hepatic neuroendocrine metastases: Does intervention alter outcomes? J Am Coll Surg 190:432–445

    Article  PubMed  CAS  Google Scholar 

  26. Chen H, Hardacre JM, Uzar A, et al. (1998) Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 187:88–93

    Article  PubMed  CAS  Google Scholar 

  27. Dominguez S, Denys A, Menu Y, et al. (1999) Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumours. Ital J Gastroenterol Hepatol 31(Suppl 2):213–215

    Google Scholar 

  28. McEntee GP, Nagorney DM, Kvols LK, et al. (1990) Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108:1091–1096

    PubMed  CAS  Google Scholar 

  29. Soreide O, Berstad T, Bakka A, et al. (1992) Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 111:48–54

    PubMed  CAS  Google Scholar 

  30. Yao KK, Talamonti MS, Nemcek A, et al. (2001) Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 130:677–685

    Article  PubMed  CAS  Google Scholar 

  31. Benevento A, Boni L, Frediani L, et al. (2000) Result of liver resection as treatment for metastases from noncolorectal cancer. J Surg Oncol 74:24–29

    Article  PubMed  CAS  Google Scholar 

  32. Grazi GL, Cescon M, Pierangeli F, et al. (2000) Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology 47:481–486

    PubMed  CAS  Google Scholar 

  33. Que FG, Nagorney DM, Batts KP, et al. (1995) Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169:36–42

    Article  PubMed  CAS  Google Scholar 

  34. Akerstrom G (1996) Management of carcinoid tumors of the stomach, duodenum, and pancreas. World J Surg 20:173–182

    PubMed  CAS  Google Scholar 

  35. Faiss S, Scherubl H, Riecken EO, et al. (1996) Drug therapy in metastatic neuroendocrine tumors of the gastroentero-pancreatic system. Recent Results Cancer Res 142:193–207

    PubMed  CAS  Google Scholar 

  36. di Bartolomeo M, Bajetta E, Buzzoni R, et al. (1996) Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77:402–408

    PubMed  Google Scholar 

  37. Moertel CG, Hanley JA (1979) Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2:327–334

    PubMed  CAS  Google Scholar 

  38. Oberg K, Norheim I, Lundqvist G, et al. (1987) Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin—alone or in combination with 5 FU. Acta Oncol 26:429–432

    PubMed  CAS  Google Scholar 

  39. Moertel CG, Lefkopoulo M, Lipsitz S, et al. (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523

    PubMed  CAS  Google Scholar 

  40. Rivera E, Ajani JA (1998) Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 21:36–38

    Article  PubMed  CAS  Google Scholar 

  41. Gray RK, Rosch J, Grollman JH (1970) Arteriography in the diagnosis of islet-cell tumors. Radiology 97:39–44

    PubMed  CAS  Google Scholar 

  42. Andersson M, Aronsen F, Balch C, et al. (1989) Pharmacokinetics of intra-arterial mitomycin-c with or without degradable starch microspheres (DSM) in the treatment of non-resectable liver cancer. Acta Oncol 28:219–222

    PubMed  CAS  Google Scholar 

  43. Ruszniewski P, Malka D (2000) Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion 62(suppl 1):79–83

    PubMed  Google Scholar 

  44. Sutcliffe R, Maguire D, Ramage J, et al. (2004) Management of neuroendocrine liver metastases Am J Surg 187:39–46

    Article  PubMed  Google Scholar 

  45. Norton JA, Warren RS, Kelly MG, et al. (2003) Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 134:1057–1063

    Article  PubMed  Google Scholar 

  46. Sarmiento JM, Heywood G, Rubin J, et al. (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197:29–37

    Article  PubMed  Google Scholar 

  47. Eriksson BK, Larsson EG, Skogseid BM, et al. (1998) Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83:2293–2301

    Article  PubMed  CAS  Google Scholar 

  48. Brown KT, Koh BY, Brody LA, et al. (1999) Particle embolization of hepatic metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 10:397–403

    PubMed  CAS  Google Scholar 

  49. Rivera E, Ajani JA (1998) Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 21:36–38

    Article  PubMed  CAS  Google Scholar 

  50. Faiss S, Pape UF, Bohmig M, et al. (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—The International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21:2689–2696

    Article  PubMed  CAS  Google Scholar 

  51. De Jong M, Breeman WA, Bernard HF, et al. (1999) Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. Q J Nucl Med 43:356–66

    PubMed  Google Scholar 

  52. Mukherjee JJ, Kaltsas GA, Islam N, et al. (2001) Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol 55:47–60

    Article  CAS  Google Scholar 

  53. Castellani MR, Chiti A, Seregni E, et al. (2000) Role of 131Imetaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. Q J Nucl Med 44:77–87

    PubMed  CAS  Google Scholar 

  54. Chatal JF, Le Bodic MF, Kraeber-Bodere F, et al. (2000) Nuclear medicine applications for neuroendocrine tumors. World J Surg 24:1285–9

    Article  PubMed  CAS  Google Scholar 

  55. Chatziioannou A, Ladopoulos C, Limouris GS, et al. (2004) Selective intraarterial injection of 111In-pentetreotide in the treatment of somatostatin positive (receptors II, SSTR2) neuroendocrine metastatic disease in the liver. CIRSE 2004, Barcelona. Poster 150

    Google Scholar 

  56. Le Treut YP, Delpero JR, Dousset B, et al. (1997) Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg 225:355–364

    PubMed  Google Scholar 

  57. Dousset B, Houssin D, Soubrane O, et al. (1995) Metastatic endocrine tumors: is there a place for liver transplantation? Liver Transpl Surg 1:111–117

    Article  PubMed  CAS  Google Scholar 

  58. Knechtle SJ, Kalayoglu M, D’Alessandro AM, et al. (1997) Proceed with caution: liver transplantation for metastatic neuroendocrine tumors. Ann Surg 225:345–346

    Article  PubMed  CAS  Google Scholar 

  59. Lang H, Oldhafer KJ, Weimann A, et al. (1997) Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 225:347–354

    Article  PubMed  CAS  Google Scholar 

  60. Coppa J, Pulvirenti A, Schiavo M, et al. (2001) Resection versus transplantation for liver metastases from neuroendocrine tumors. Transplant Proc 33:1537–1539

    Article  PubMed  CAS  Google Scholar 

  61. Perry LJ, Stuart K, Stokes KR, et al. (1994) Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 116:1111–1116

    PubMed  CAS  Google Scholar 

  62. Drougas JG, Antony LB, Blair TK, et al. (1998) Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg 175:408–412

    Article  PubMed  CAS  Google Scholar 

  63. Kim YH, Ajani JA, Carrasco CH, et al. (1999) Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 17:474–478

    PubMed  CAS  Google Scholar 

  64. Roche A, Girish BV, de Baere T, et al. (2003) Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 13:136–140

    PubMed  Google Scholar 

  65. Schell SR, Camp RE, Caridi JG, et al. (2002) Hepatic Artery Embolization for Control of Symptoms, Octreotide Requirements, and Tumor Progression in Metastatic Carcinoid Tumors. J Gastrointest Surg 6:664–670

    Article  PubMed  Google Scholar 

  66. Winkelbauer FW, Niederle B, Pietschmann F (1995) Hepatic artery embolotherapy of hepatic metastases from carcinoid tumors: value of using a mixture of cyanoacrylate and ethiodized oil. Am J Roentgenol 165:323–327

    CAS  Google Scholar 

  67. Stokes KR, Stuart K, Clouse ME (1993) Hepatic arterial chemoembolization for metastatic endocrine tumors. J Vasc Interv Radiol 4:341–345

    PubMed  CAS  Google Scholar 

  68. Hartnell GG, Gates J, Stuart K, et al. (1999) Hepatic chemoembolization: effect of intraarterial lidocaine on pain and postprocedure recovery. Cardiovasc Intervent Radiol 22:293–297

    Article  PubMed  CAS  Google Scholar 

  69. Clouse ME, Perry L, Stuart K, et al. (1994) Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 55(suppl 3):92–97

    PubMed  Google Scholar 

  70. Lem SL, Asch M, Kachura JR, et al. (2004) Toronto hepatic artery embolization study. J Vasc Interv Radiol 15:S245 [Poster No. 297 presented at 29th Annual Scientific Meeting of the Society of Interventional Radiology, Phoenix, Arizona, March 25–30, 2004]

    Google Scholar 

  71. Pentecost MJ, Daniels JR, Teitelbaum GP, et al. (1993) Hepatic chemoembolization: safety with portal vein thrombosis. J Vasc Intervent Radiol 4:347–351

    CAS  Google Scholar 

  72. Gates J, Hartnell GG, Stuart KE, et al. (1999) Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Radiographics 19:399–414

    PubMed  CAS  Google Scholar 

  73. Carrasco CH, Charnsangavej C, Ajani J, et al. (1986) The carcinoid syndrome: palliation by hepatic artery embolization. Am J Roentgenol 147:149–154

    CAS  Google Scholar 

  74. Marlink RG, Lokich JJ, Robins JR, et al. (1990) Hepatic arterial embolization for metastatic hormone-secreting tumors. Technique, effectiveness, and complications. Cancer 65:2227–2232

    PubMed  CAS  Google Scholar 

  75. Hajarizadeh H, Ivancev K, Mueller CR, et al. (1992) Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate. Am J Surg 163:479–483

    Article  PubMed  CAS  Google Scholar 

  76. Ishikawa H, Kanai T, Ono T, et al. (1994) Analysis of cases with liver abscess following transcatheter arterial chemoembolization (TAE) for malignant hepatic tumors (Japanese). Gan To Kagaku Ryoho 21:2233–2236

    PubMed  CAS  Google Scholar 

  77. Song SY, Chung JW, Han JK, et al. (2001) Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 12:313–320

    PubMed  CAS  Google Scholar 

  78. Kim W, Clark TW, Baum RA, et al. (2001) Risk factors for liver abscess formation after hepatic chemoembolization J Vasc Interv Radiol 12:965–968

    PubMed  CAS  Google Scholar 

  79. Geschwind JF, Kaushik S, Ramsey DE, et al. (2002) Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. J Vasc Interv Radiol 13:1163–1166

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Vascular and Interventional Radiology, Department of Medical Imaging, Toronto General Hospital, 585 University Avenue, NCSB 1C-563, Toronto, Ontario, Canada, M5G 2N2

    Kong Teng Tan MB, BCh, FRCS, FRCR

  2. Division of Vascular and Interventional Radiology, Department of Medical Imaging, Toronto General Hospital, 200 Elizabeth Street, Eaton South 1-454d, Toronto, Ontario, Canada, M5G 2C4

    John R. Kachura MD, FRCPC

Authors
  1. Kong Teng Tan MB, BCh, FRCS, FRCR
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John R. Kachura MD, FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Carver College of Medicine, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA, 52242, USA

    Jafar Golzarian MD (Professor of Radiology, Department of Radiology) & Shiliang Sun MD (Associate Professor of Radiology) (Professor of Radiology, Department of Radiology) &  (Associate Professor of Radiology)

  2. Departments of Radiology and Surgery, University of Iowa Hospitals and Clinics, Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA, 52242, USA

    M. J. Sharafuddin MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Tan, K.T., Kachura, J.R. (2006). Embolotherapy for Neuroendocrine Tumor Hepatic Metastases. In: Golzarian, J., Sun, S., Sharafuddin, M.J. (eds) Vascular Embolotherapy. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-33257-X_14

Download citation

  • DOI: https://doi.org/10.1007/3-540-33257-X_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-21491-5

  • Online ISBN: 978-3-540-33257-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation